0R6Y Stock Overview
Produces and supplies alpha-particle emitters for cancer therapy in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Thor Medical ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.73 |
| 52 Week High | NOK 3.43 |
| 52 Week Low | NOK 1.01 |
| Beta | 0 |
| 1 Month Change | -20.52% |
| 3 Month Change | 98.40% |
| 1 Year Change | 109.52% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R6Y | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.4% | 3.3% | 1.3% |
| 1Y | 109.5% | -23.4% | 4.3% |
Return vs Industry: 0R6Y exceeded the UK Biotechs industry which returned -23.9% over the past year.
Return vs Market: 0R6Y exceeded the UK Market which returned 3.9% over the past year.
Price Volatility
| 0R6Y volatility | |
|---|---|
| 0R6Y Average Weekly Movement | 23.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R6Y's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0R6Y's weekly volatility has increased from 14% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 5 | Jasper Kurth | www.thormedical.no |
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.
Thor Medical ASA Fundamentals Summary
| 0R6Y fundamental statistics | |
|---|---|
| Market cap | NOK 639.99m |
| Earnings (TTM) | -NOK 18.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-34.5x
P/E RatioIs 0R6Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R6Y income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 18.56m |
| Earnings | -NOK 18.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0R6Y perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 10:47 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Thor Medical ASA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|